Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
![Foto de Cancer Center Clínica Universidad de Navarra (CCUN)](/img/uploaded/C185D7383C9859310EFAE5D78F321270.jpg)
![Foto de University of Sydney](/img/noimage_org.png)
University of Sydney
Sídney, AustraliaPublicaciones en colaboración con investigadores/as de University of Sydney (27)
2024
-
AI is a viable alternative to high throughput screening: a 318-target study
Scientific Reports, Vol. 14, Núm. 1
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
-
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients
Seminars in Hematology
-
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients
Seminars in Hematology
2022
-
Oncoplastic breast consortium recommendations for mastectomy and whole breast reconstruction in the setting of post-mastectomy radiation therapy
Breast, Vol. 63, pp. 123-139
-
SLC7A8 coding for LAT2 is associated with early disease progression in osteosarcoma and transports doxorubicin
Frontiers in Pharmacology, Vol. 13
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
2019
-
Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
Clinical Gastroenterology and Hepatology, Vol. 17, Núm. 11, pp. 2320-2329.e12
-
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy
European Journal of Cancer, Vol. 117, pp. 99-106
2018
-
A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers
Brain, Vol. 141, Núm. 10, pp. 2895-2907
-
Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis
Journal of Hepatology, Vol. 69, Núm. 2, pp. 396-405
-
Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: Influence of chemotherapy on efficacy and safety
Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2395-2404
-
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 11, pp. 1530-1542
2017
-
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
The Lancet, Vol. 390, Núm. 10094, pp. 555-566
-
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials
The Lancet Oncology, Vol. 18, Núm. 9, pp. 1159-1171
-
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecologic Oncology, Vol. 144, Núm. 1, pp. 65-71
2016
-
SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (Plus or Minus Bevacizumab) versus mFOLFOX6 (Plus or Minus Bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer
Journal of Clinical Oncology, Vol. 34, Núm. 15, pp. 1723-1731